name: CT55_HUMAN Cancer/testis antigen 55 (sprot)

description: A protein that is a translation product of the CT55 gene in human.


name: VOPP1_HUMAN WW domain binding protein VOPP1 (sprot)

description: A WW domain binding protein VOPP1 that is encoded in the genome of human.


Fractured carpal bone

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A partial or complete breakage of the carpal bone.


name: HCDH_HUMAN Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (sprot)

description: A hydroxyacyl-coenzyme A dehydrogenase, mitochondrial that is encoded in the genome of human.


pleural solitary fibrous tumor

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A localized neoplasm of probable fibroblastic derivation, that arises from the pleura. It is characterized by the presence of round to spindle-shaped cells, hylanized stroma formation, thin-walled branching blood vessels, and thin bands of collagen.


CPNE5_HUMAN Copine-5 (sprot)

A copine-5 that is encoded in the genome of human.


CPNE9_HUMAN Copine-9 (sprot)

A copine-9 that is encoded in the genome of human.


emphysematous cholecystitis

description: Cholecystitis resulting from infection by gas producing organisms.


name: PLAT1_HUMAN Phospholipase A and acyltransferase 1 (sprot)

description: An HRAS-like suppressor that is encoded in the genome of human.


name: CDKA2_HUMAN Cyclin-dependent kinase 2-associated protein 2 (sprot)

description: A cyclin-dependent kinase 2-associated protein 2 that is encoded in the genome of human.


name: LMBL1_HUMAN Lethal(3)malignant brain tumor-like protein 1 (sprot)

description: A lethal(3)malignant brain tumor-like protein 1 that is encoded in the genome of human.


N-acetylanthranilic acid

An amidobenzoic acid consisting of anthranilic acid carrying an N-acetyl group.


name: Mixed respiratory and metabolic acidosis


name: PRT1B_HUMAN Proline rich transmembrane protein 1B (sprot)

description: A protein that is a translation product of the PRRT1B gene in human.


name: DUSTY_HUMAN Dual serine/threonine and tyrosine protein kinase (sprot)

description: A dual serine/threonine and tyrosine protein kinase that is encoded in the genome of human.


silicotuberculosis

description: Tuberculosis caused by the infection of Mycobacterium tuberculosis in patients with silicosis (that is caused by inhalation of silica dust particles). The risk of a patient with silicosis developing pulmonary tuberculosis and extra-pulmonary tuberculosis is higher than in healthy population.


ACECAINIDE

A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.


name: EIF3J_HUMAN Eukaryotic translation initiation factor 3 subunit J (sprot)

description: A eukaryotic translation initiation factor 3 subunit J that is encoded in the genome of human.


O-acetylcarnitine

An O-acylcarnitine having acetyl as the acyl substituent.


name: TM9S1_HUMAN Transmembrane 9 superfamily member 1 (sprot)

description: A transmembrane 9 superfamily member 1 that is encoded in the genome of human.


ATCAY_HUMAN Caytaxin (sprot)

A caytaxin that is encoded in the genome of human.


name: DNJC9_HUMAN DnaJ homolog subfamily C member 9 (sprot)

description: A DnaJ homolog subfamily C member 9 that is encoded in the genome of human.


Brown syndrome

description: Brown syndrome is a rare eye disorder characterized by defects in eye movements caused by abnormalities of the superior oblique tendon sheath of the superior oblique muscle.


name: TDRD6_HUMAN Tudor domain-containing protein 6 (sprot)

description: A tudor domain-containing protein 6 that is encoded in the genome of human.


name: disease arising from reactivation of latent virus

description: An infectious disease that arises from reactivation of a virus from a latent phase to a lytic phase.


name: POTEE_HUMAN POTE ankyrin domain family member E (sprot)

description: A POTE ankyrin domain family member E that is encoded in the genome of human.


hematohidrosis

description: Hematohidrosis is a rare condition characterized by blood oozing from intact skin and mucosa. Signs and symptoms include sweating blood, crying bloody tears, bleeding from the nose, bleeding from the ears, or oozing bloodfrom other skin surfaces. The episodes are usually self-limiting.


name: CL18A_HUMAN C-type lectin domain family 18 member A (sprot)

description: A C-type lectin domain family 18 member A that is encoded in the genome of human.


intraductal papilloma

description: An intraluminal papillary epithelial neoplasm arising within the ducts. Representative examples are the intraductal breast papilloma and the salivary gland intraductal papilloma.


name: BAFL_HUMAN Barrier-to-autointegration factor-like protein (sprot)

description: A barrier-to-autointegration factor-like protein that is encoded in the genome of human.


name: EOGT_HUMAN EGF domain-specific O-linked N-acetylglucosamine transferase (sprot)

description: An EGF domain-specific O-linked N-acetylglucosamine transferase that is encoded in the genome of human.


name: PRDM7_HUMAN Histone-lysine N-methyltransferase PRDM7 (sprot)

description: A histone-lysine N-methyltransferase PRDM7 that is encoded in the genome of human.


name: PTG3L_HUMAN Putative protein PTGES3L (sprot)

description: A protein PTGES3L that is encoded in the genome of human.


name: KI2S3_HUMAN Killer cell immunoglobulin-like receptor 2DS3 (sprot)

description: A killer cell immunoglobulin-like receptor 2DS3 that is encoded in the genome of human.


acrivastine

A member of the class of pyridines that is (pyridin-2-yl)acrylic acid substituted at position 6 by a [(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl group. It is a non-sedating antihistamine used for treatment of hayfever, urticaria, and rhinitis.


propiomazine

A member of the class of  phenothiazines that is 10H-phenothiazine substituted by a 2-(dimethylamino)propyl group at nitrogen atom and a propanoyl group at position 2.


iodamide

A benzoic acid compound having iodo substituents at the 2-, 4- and 6-positions, an acetamido substituent at the 3-position and an acetamidomethyl substituent at the 5-position.


name: GFRP_HUMAN GTP cyclohydrolase 1 feedback regulatory protein (sprot)

description: A GTP cyclohydrolase 1 feedback regulatory protein that is encoded in the genome of human.


Astasia

description: A postural abnormality characterized by the inability to stand without external support despite having sufficient muscle strength.


DCNL3_HUMAN DCN1-like protein 3 (sprot)

A DCN1-like protein 3 that is encoded in the genome of human.


bis(2-chloroethyl) sulfide

An ethyl sulfide that is diethyl sulfide in which a hydrogen from each of the terminal methyl groups is replaced by a chlorine. It is a powerful vesicant regulated under the Chemical Weapons Convention.


name: RNFT2_HUMAN E3 ubiquitin-protein ligase RNFT2 (sprot)

description: An E3 ubiquitin-protein ligase RNFT2 that is encoded in the genome of human.


brodimoprim

An aminopyrimidine that is 2,4-diaminopyrimidine in which the hydrogen at position 5 has been replaced by a 4-bromo-3,5-dimethoxybenzyl group.


name: myeloid neoplasm associated with PDGFRB rearrangement

description: A rare, malignant, neoplastic disease characterized by clonal proliferation of myeloid and/or lymphoid precursors harboring rearrangements in the PDGFRB gene, in the blood, bone marrow and often other tissues as well (spleen, lymph nodes, skin, etc.). It usually presents as chronic myelomonocytic leukemia with eosinophilia, chronic eosinophilic leukemia, atypical chronic myelogenous leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome, acute myeloid leukemia or acute lymphoblastic leukemia. Patients usually present with anemia, leukocytosis, monocytosis, eosinophilia and/or splenomegaly, or systemic symptoms, such as fever, sweating and/or weight loss.


2,4-dichlorobenzoic acid

A chlorobenzoic acid that is benzoic acid in which the ring hydrogens at positions 2 and 4 are substituted by chloro groups.


subacute thyroiditis

description: Self-limited inflammation of the thyroid gland characterized by the presence of multinucleated giant cells. Patients present with neck pain, often associated with fever and dysphagia. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function.


name: S3TC1_HUMAN SH3 domain and tetratricopeptide repeat-containing protein 1 (sprot)

description: An SH3 domain and tetratricopeptide repeat-containing protein 1 that is encoded in the genome of human.


name: C16L2_HUMAN CD164 sialomucin-like 2 protein (sprot)

description: A CD164 sialomucin-like 2 protein that is encoded in the genome of human.


name: H2A1J_HUMAN Histone H2A type 1-J (sprot)

description: A histone H2A type 1-J that is encoded in the genome of human.


jugulotympanic paraganglioma

description: A benign or malignant extra-adrenal parasympathetic paraganglioma arising from paraganglia in the base of the skull and middle ear.


LFG1_HUMAN Protein lifeguard 1 (sprot)

A glutamate [NMDA] receptor-associated protein 1 that is encoded in the genome of human.


name: ectodermal dysplasia and immune deficiency

description: A rare disorder caused by mutations either in the IKBKG gene resulting in an X-linked recessive inheritance pattern or in the NFKBIA gene resulting in an autosomal dominant inheritance pattern. It is characterized by abnormal development of ectodermal tissues including the skin, hair, teeth, and sweat glands and immune system deficiency. It results in dry and wrinkled skin, sparse scalp and body hair, missing teeth, and reduced ability to sweat. Patients have abnormally low levels of antibodies causing inability to fight infections.


Becker nevus syndrome

description: Becker nevus syndrome is characterized by the presence of a Becker nevus in association with underdevelopment (hypoplasia) of the breast or other skin-related, muscular, or skeletal defects, all of which usually involve the same side of the bodyas the nevus (ipsilateral). Specific signs and symptoms in addition to the nevus may include ipsilateral breast hypoplasia; skeletal abnormalities such ashypoplasia of the shoulder girdle, scoliosis, fused ribs, and ipsilateral shortness of the arm; and several other features. Thecondition is thought to be sporadic (occurring in individuals with no history of the condition in the family). Treatment varies depending upon the specific symptoms present and the extent of the condition in the affected individual.


HMN10_HUMAN Humanin-like 10 (sprot)

A humanin-like 10 that is encoded in the genome of human.


sodium thiosulfate

An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.


name: OTU7A_HUMAN OTU domain-containing protein 7A (sprot)

description: An OTU domain-containing protein 7A that is encoded in the genome of human.


gadodiamide

The hydrate of gadodiamide.


myoclonic dystonia 11

description: Any myoclonus-dystonia syndrome in which the cause of the disease is a mutation in the SGCE gene.


apnea of prematurity

description: Apnea of prematurity is a developmental disorder affecting premature infants, likely secondary to an immaturity of respiratory control resulting in idiopathic pauses in breathing often associated with reduced heart rate and arterial blood oxygen levels. It may be exacerbated by concurrent neonatal diseases.


vitamin K-antagonist embryofetopathy

description: A teratogenic disorder observed in a newborn or child of a mother who was exposed to warfarin during pregnancy. Manifestations include nasal bridge depression, nasal bones hypoplasia, microcephaly, congenital heart disorders, and brachydactyly.


Hyponatriuria

description: An abnormally decreased sodium concentration in the urine.


name: FCRL6_HUMAN Fc receptor-like protein 6 (sprot)

description: An Fc receptor-like protein 6 that is encoded in the genome of human.


PHENYL ETHANOL

An aromatic alcohol that is ethanol substituted by a phenyl group at position 1.


platelet-type bleeding disorder 10

description: Any inherited bleeding disorder, platelet-type in which the cause of the disease is a mutation in the CD36 gene.


name: RTRAF_HUMAN RNA transcription, translation and transport factor protein (sprot)

description: A protein C14orf166 that is encoded in the genome of human.


46,XY complete gonadal dysgenesis

description: 46,XY complete gonadal dysgenesis (46,XY CGD) is a disorder of sex development (DSD) associated with anomalies in gonadal development that result in the presence of female external and internal genitalia despite the 46,XY karyotype.


FA13B_HUMAN Protein FAM13B (sprot)

A protein FAM13B that is encoded in the genome of human.


HALOXYFOP-R-METHYL

A 2-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoic acid that has R configuration. It is the most active enantiomer of the (racemic) herbicide haloxyfop and is used (particularly as the corresponding methyl and ethoxyethyl ester proherbicides (haloxyfop-P-methyl and haloxyfop-P-etotyl, respectively) to control annual and perrenial grasses in a variety of crops.


JTB_HUMAN Protein JTB (sprot)

A protein JTB that is encoded in the genome of human.


A 5-alkylresorcinol that is resorcinol which is substituted by a heptadecyl group at position 5. It is found in wheat bran.


name: OXND1_HUMAN Oxidoreductase NAD-binding domain-containing protein 1 (sprot)

description: An oxidoreductase NAD-binding domain-containing protein 1 that is encoded in the genome of human.


name: DNA-(apurinic or apyrimidinic site) endonuclease, initiator methionine removed form (human)

description: A DNA-(apurinic or apyrimidinic site) endonuclease (human) that has had the initiator methionine removed. UniProtKB:P27695, 2-318.


Obstructive Ureterocele

description: A ureterocele with a small, obstructive orifice.


ureterocele

description: A cystic and dysplastic dilation of the distal ureter within the bladder that may extend into the bladder neck and urethra.


Orthotopic ureterocele

description: A ureterocele that is located entirely within the bladder, and which may be associated with a single system, with the upper pole ureter of a completely duplicated system, or rarely associated with a lower pole ureter. (Adapted from Glassberg KI, Braren V, Duckett JW, Jacobs EC, King LR, Lebowitz RL et al. Suggested terminology for duplex systems, ectopic ureters and ureteroceles. J Urol 1984; 132(6):1153-1154.)


Sphincteric Ureterocele

description: A ureterocele in which the orifice is distal to the external urinary sphincter.


Cecoureterocele

description: A ureterocele in which the orifice is located in the bladder, with the ureterocele pouch extending submucosally into the urethra.


Ectopic ureterocele

description: A ureterocele in which some portion of the ureterocele is situated permanently at the bladder neck or in the urethra. The orifice may be situated in the bladder, at the bladder neck, or in the urethra. (Adapted from Glassberg KI, Braren V, Duckett JW, Jacobs EC, King LR, Lebowitz RL et al. Suggested terminology for duplex systems, ectopic ureters and ureteroceles. J Urol 1984; 132(6):1153-1154.)


name: eukaryotic translation initiation factor 4E phosphorylated 1 (human)

description: A eukaryotic translation initiation factor 4E (human) that has been phosphorylated on the residue at the position equivalent to Ser-53 of the amino acid sequence represented by UniProtKB:P06730-1. Example: UniProtKB:P06730-1, Ser-53, MOD:00046.


An Axin that is a translation product of the human AXIN1 gene or a 1:1 ortholog thereof.


Axin-1 isoform 1 (human)

An Axin-1 isoform 1 that is encoded in the genome of human.


Axin-1 ubiquitinated 1 (human)

An Axin-1 (human) that has been ubiquitinated on the residue at the position equivalent to Lys-501 of the amino acid sequence represented by UniProtKB:O15169. UniProtKB:O15169, Lys-501, MOD:01148.


Axin-1 sequence variant L396M (human)

An Axin-1 (human) that has a Met residue at the position equivalent to Leu-396 of the amino acid sequence represented by UniProtKB:O15169-1. Example: UniProtKB:O15169-1, Leu-396, CHEBI:16044.


Axin-1 ADP-ribosylated form (human)

An Axin-1 (human) that includes at least one ADP-ribosylated residue. UniProtKB:O15169, MOD:00752.


Axin-1 isoform 2 (human)

An Axin-1 isoform 2 that is encoded in the genome of human.


Axin-1 phosphorylated 1 (human)

An Axin-1 (human) that has been phosphorylated on the residue at the position equivalent to Thr-481, and phosphoserine at positions 486 and 493 of the amino acid sequence represented by UniProtKB:O15169. UniProtKB:O15169, Thr-481, MOD:00047|Ser-486/Ser-493, MOD:00046.


Axin-1 sequence variant Y346* (human)

An Axin-1 (human) that has has been truncated after the position equivalent to Pro-345 of the amino acid sequence represented by UniProtKB:O15169-1. Example: UniProtKB:O15169-1, 1-345.


name: Axin-1 ADP-ribosylated and ubiquitinated form (human)

description: An Axin-1 (human) that includes at least one ADP-ribosylated residue and at least one ubiquitinated lysine. UniProtKB:O15169, MOD:00752|MOD:01148.


Axin-1 sequence variant R354L (human)

An Axin-1 (human) that has a Leu residue at the position equivalent to Arg-354 of the amino acid sequence represented by UniProtKB:O15169-1. Example: UniProtKB:O15169-1, Arg-354, CHEBI:30006.


Axin-1 sequence variant W247* (human)

An Axin-1 (human) that has has been truncated after the position equivalent to Glu-246 of the amino acid sequence represented by UniProtKB:O15169-1. Example: UniProtKB:O15169-1, 1-246.


Axin-1 sequence variant E255S (human)

An Axin-1 (human) that has a Ser residue at the position equivalent to Glu-255 of the amino acid sequence represented by UniProtKB:O15169-1. Example: UniProtKB:O15169-1, Glu-255, CHEBI:29999.


Axin-1 sequence variant E406* (human)

An Axin-1 (human) that has has been truncated after the position equivalent to Ala-405 of the amino acid sequence represented by UniProtKB:O15169-1. Example: UniProtKB:O15169-1, 1-405.


name: circadian locomoter output cycles protein kaput cysteinylated 1 (human)

description: A circadian locomoter output cycles protein kaput (human) that has been cysteinylated on the residue at the position equivalent to Cys-337 of the amino acid sequence represented by UniProtKB:O15516. UniProtKB:O15516, Cys-337, MOD:00765.


name: zinc-alpha-2-glycoprotein N-glycosylated 33 (human)

description: A zinc-alpha-2-glycoprotein (human) that has been N-glycosylated at the residue equivalent to Asn-128 of the amino acid sequence represented by UniProtKB:P25311-1, in which the glycan composition is represented by GlyTouCan:G60923RB. Example: UniProtKB:P25311-1, Asn-128, MOD:00160~GNO:G60923RB.


taurodontism

description: Taurodontism is a dental anomaly characterized by an elongated pulp chamber, displaced toward the apical floor of the tooth with no constriction at the level of the cemento-enamel junction, and short roots. It most frequently affects permanent molar teeth. Taurodontism increases the risk of pulp exposure. It can be isolated or associated with certain syndromes such as Down syndrome, amelogenesis imperfecta, and Klinefelter syndrome.


A N-oxide isolated from Streptoalloteichus sp.1454-19. It is a siderophore which exhibits immunosuppressive activity on a mixed lymphocyte culture reaction (MLCR).


name: myasthenic syndrome, congenital, 23, presynaptic


name: nephrolithiasis susceptibility caused by SLC26A1


name: serine/threonine-protein kinase VRK2 isoform h4 (human)

description: A serine/threonine-protein kinase VRK2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q86Y07-4.


Postsurgical Stage II Hepatoblastoma

description: No metastases, tumor grossly resected with microscopic residual disease (i.e., positive margins); or tumor rupture, or tumor spill at the time of surgery. (from PDQ 2004)


prolargin O-glycosylated 6 (human)

A prolargin (human) that has been O-glycosylated at the residue equivalent to Thr-56 of the amino acid sequence represented by UniProtKB:P51888-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:P51888-1, Thr-56, MOD:00005~GNO:G53434XO.


name: potassium voltage-gated channel subfamily H member 5 isoform 3 (human)

description: A voltage-gated potassium channel KCNH5 isoform 3 that is encoded in the genome of human.


primary ciliary dyskinesia 4

description: A primary ciliary dyskinesia that is characterized by partial absence of the inner dynein arms with variable occurrence of situs inversus and has material basis in variation in the chromosome region 15q13.1-q15.1.


mucin-1 O-glycosylated 9 (human)

A mucin-1 (human) that has been O-glycosylated at the residue equivalent to Thr-919 of the amino acid sequence represented by UniProtKB:P15941-1, in which the glycan composition is represented by GlyTouCan:G58001LT. Example: UniProtKB:P15941-1, Thr-919, MOD:00005~GNO:G58001LT.


name: ETS domain-containing transcription factor ERF isoform h2 (human)

description: An ETS domain-containing transcription factor ERF (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P50548-2.


name: heat shock protein 105 kDa deaminated 2 (human)

description: A heat shock protein 105 kDa (human) that has been deaminated on the residue at the position equivalent to Asn-96 of the amino acid sequence represented by UniProtKB:Q92598-1. Example: UniProtKB:Q92598-1, Asn-96, MOD:00684.


HSPH protein

An Hsp70 family chaperone that has its ATP-binding and substrate-binding domains separated by a linker domain of over 100 amino acids. Proteins in this class function generally as nucleotide exchange factors for cytosolic Hsp70s.


name: heat shock protein 105 kDa isoform Beta (human)

description: A heat shock protein 105 kDa isoform 2 that is encoded in the genome of human.


name: heat shock 70 kDa protein 4 methylated 1 (human)

description: A heat shock 70 kDa protein 4 (human) that has been methylated on the residue at the position equivalent to Cys-270 of the amino acid sequence represented by UniProtKB:P34932-1. Example: UniProtKB:P34932-1, Cys-270, MOD:00660.


name: heat shock protein 105 kDa methylated 1 (human)

description: A heat shock protein 105 kDa (human) that has been methylated on the residue at the position equivalent to Cys-167 of the amino acid sequence represented by UniProtKB:Q92598-1. Example: UniProtKB:Q92598-1, Cys-167, MOD:00660.


name: heat shock protein 105 kDa methylated 3 (human)

description: A heat shock protein 105 kDa (human) that has been methylated on the residue at the position equivalent to Cys-658 of the amino acid sequence represented by UniProtKB:Q92598-1. Example: UniProtKB:Q92598-1, Cys-658, MOD:00660.


heat shock 70 kDa protein 4L

An HSPH protein that is a translation product of the human HSPA4L gene or a 1:1 ortholog thereof.


name: heat shock 70 kDa protein 4 isoform 1 (human)

description: A heat shock 70 kDa protein 4 isoform 1 that is encoded in the genome of human.


name: heat shock 70 kDa protein 4 isoform h2 (human)

description: A heat shock 70 kDa protein 4 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P34932-2.


name: heat shock protein 105 kDa cysteinylated 1 (human)

description: A heat shock protein 105 kDa (human) that has been cysteinylated on the residue at the position equivalent to Cys-213 of the amino acid sequence represented by UniProtKB:Q92598-1. Example: UniProtKB:Q92598-1, Cys-213, MOD:00765.


name: heat shock 70 kDa protein 4 cysteinylated 1 (human)

description: A heat shock 70 kDa protein 4 (human) that has been cysteinylated on the residue at the position equivalent to Cys-270 of the amino acid sequence represented by UniProtKB:P34932-1. Example: UniProtKB:P34932-1, Cys-270, MOD:00765.


name: heat shock 70 kDa protein 4L methylated 2 (human)

description: A heat shock 70 kDa protein 4L (human) that has been methylated on the residue at the position equivalent to Cys-376 of the amino acid sequence represented by UniProtKB:O95757. UniProtKB:O95757, Cys-376, MOD:00660.


name: heat shock protein 105 kDa isoform Alpha (human)

description: A heat shock protein 105 kDa isoform 1 that is encoded in the genome of human.


name: heat shock protein 105 kDa deaminated 1 (human)

description: A heat shock protein 105 kDa (human) that has been deaminated on the residue at the position equivalent to Gln-116 of the amino acid sequence represented by UniProtKB:Q92598-1. Example: UniProtKB:Q92598-1, Gln-116, MOD:00685.


name: heat shock protein 105 kDa isoform h4 (human)

description: A heat shock protein 105 kDa (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q92598-4.


name: heat shock 70 kDa protein 4L methylated 1 (human)

description: A heat shock 70 kDa protein 4L (human) that has been methylated on the residue at the position equivalent to Cys-270 of the amino acid sequence represented by UniProtKB:O95757. UniProtKB:O95757, Cys-270, MOD:00660.


name: heat shock 70 kDa protein 4 methylated 2 (human)

description: A heat shock 70 kDa protein 4 (human) that has been methylated on the residue at the position equivalent to Cys-779 of the amino acid sequence represented by UniProtKB:P34932-1. Example: UniProtKB:P34932-1, Cys-779, MOD:00660.


name: heat shock protein 105 kDa deaminated 3 (human)

description: A heat shock protein 105 kDa (human) that has been deaminated on the residue at the position equivalent to Asn-61 of the amino acid sequence represented by UniProtKB:Q92598-1. Example: UniProtKB:Q92598-1, Asn-61, MOD:00684.


name: heat shock protein 105 kDa isoform h3 (human)

description: A heat shock protein 105 kDa (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q92598-3.


name: heat shock 70 kDa protein 4 cysteinylated 2 (human)

description: A heat shock 70 kDa protein 4 (human) that has been cysteinylated on the residue at the position equivalent to Cys-213 of the amino acid sequence represented by UniProtKB:P34932-1. Example: UniProtKB:P34932-1, Cys-213, MOD:00765.


heat shock protein 105 kDa

An HSPH protein that is a translation product of the human HSPH1 gene or a 1:1 ortholog thereof.


name: heat shock protein 105 kDa methylated 2 (human)

description: A heat shock protein 105 kDa (human) that has been methylated on the residue at the position equivalent to Cys-213 of the amino acid sequence represented by UniProtKB:Q92598-1. Example: UniProtKB:Q92598-1, Cys-213, MOD:00660.


heat shock 70 kDa protein 4

An HSPH protein that is a translation product of the human HSPA4 gene or a 1:1 ortholog thereof.


name: heat shock 70 kDa protein 4L cysteinylated 1 (human)

description: A heat shock 70 kDa protein 4L (human) that has been cysteinylated on the residue at the position equivalent to Cys-270 of the amino acid sequence represented by UniProtKB:O95757. UniProtKB:O95757, Cys-270, MOD:00765.


14-3-3 protein gamma isoform 1 (human)

A 14-3-3 protein gamma isoform 1 that is encoded in the genome of human.


name: Ral guanine nucleotide dissociation stimulator-like 3 isoform h1 (human)

description: A Ral guanine nucleotide dissociation stimulator-like 3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q3MIN7-1.


Deviation of finger

description: Deviated fingers is a term that should be used if one or more fingers of the hand are deviated from their normal position, either to the radial or ulnar side. A deviation of a finger can be caused by an abnormal form of one or more of the phalanges of the affected finger, or by a deviation or displacement of one or more phalanges.


Ulnar deviation of the 4th finger

description: Displacement of the 4th finger towards the ulnar side (i.e., towards the 5th finger).


Radial deviation of the 4th finger

description: Displacement of the 4th finger towards the radial side (i.e., towards the thumb).


Radial deviation of the 2nd finger

description: Displacement of the 2nd finger towards the radial side.


Ulnar deviation of thumb

description: Bending or curvature of a thumb towards the ulnar side (towards the ring finger).


Deviation of the 2nd finger

description: Displacement of the 2nd finger from its normal position.


Distally placed thumb

description: Insertion of thumb at a more distal location than normal.


Ulnar deviation of the 5th finger

description: Displacement of the 5th finger towards the ulnar side.


Radial deviation of the 3rd finger

description: Displacement of the 3rd finger towards the radial side (i.e., towards the thumb).


Ulnar deviation of the 2nd finger

description: Displacement of the 2nd (index) finger towards the ulnar side.


Hitchhiker thumb

description: With the hand relaxed and the thumb in the plane of the palm, the axis of the thumb forms an angle of at least 90 degrees with the long axis of the hand.


Ulnar deviation of finger

description: Bending or curvature of a finger toward the ulnar side (i.e., away from the thumb). The deviation is at the metacarpal-phalangeal joint, and this finding is distinct from clinodactyly.


Clinodactyly of the 5th finger

description: Clinodactyly refers to a bending or curvature of the fifth finger in the radial direction (i.e., towards the 4th finger).


Deviation of the 5th finger

description: Displacement of the 5th finger from its normal position.


Overlapping fingers

description: A finger resting on the dorsal surface of an adjacent digit when the hand is at rest.


name: Fifth finger distal phalanx clinodactyly

description: Bending or curvature of the distal phalanx of little finger in the radial direction (i.e., towards the 4th finger).


Proximal placement of thumb

description: Proximal mislocalization of the thumb.


Ulnar deviation of the 3rd finger

description: Displacement of the 3rd finger towards the ulnar side (i.e., towards the ring finger).


Radial deviation of finger

description: Bending or curvature of a finger toward the radial side (i.e., towards the thumb). The deviation is at the metacarpal-phalangeal joint, and this finding is distinct from clinodactyly.


Deviation of the thumb

description: Displacement of the thumb from its normal position.


Deviation of the 4th finger

description: Displacement of the 4th finger from its normal position.


Deviation of the 3rd finger

description: Displacement of the 3rd finger from its normal position.


name: collagen alpha-1(XVI) chain, signal peptide removed 3-hydroxy-proline, 4-hydroxy-proline, and galactosylhydroxylysine form (human)

description: A collagen alpha-1(XVI) chain (human) that has had the signal peptide removed and that includes at least 1 3-hydroxy-proline, at least 1 galactosylhydroxylated lysine, and at least 3 4-hydroxy-prolines. Example: UniProtKB:Q07092-1, 22-1604, MOD:00038|MOD:00039(3+)|MOD:01914.


adiponectin O-glycosylated 1 (human)

An adiponectin (human) that has been O-glycosylated at the residue equivalent to Thr-21 of the amino acid sequence represented by UniProtKB:Q15848-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:Q15848-1, Thr-21, MOD:00005~GNO:G53434XO.


name: DnaJ homolog subfamily C member 12 isoform a (human)

description: A DnaJ homolog subfamily C member 12 isoform 1 that is encoded in the genome of human.


name: Premature birth following premature rupture of fetal membranes


Premature rupture of membranes

description: Premature rupture of membranes (PROM) is a condition which occurs in pregnancy when the amniotic sac ruptures more than an hour before the onset of labor.


Preterm premature rupture of membranes

description: PPROM (preterm premature rupture of membranes) occurs at less than 37 weeks of gestation. PPROM can happen spontaneously, during preterm labor, or following a procedure such as amniocentesis.


name: high mobility group protein 20A phosphorylated 1 (human)

description: A high mobility group protein 20A (human) that has been phosphorylated on the residue at the position equivalent to Ser-105 of the amino acid sequence represented by UniProtKB:Q9NP66-1. Example: UniProtKB:Q9NP66-1, Ser-105, MOD:00046.


name: alpha-N-acetylgalactosaminidase N-glycosylated 30 (human)

description: An alpha-N-acetylgalactosaminidase (human) that has been N-glycosylated at the residue equivalent to Asn-177 of the amino acid sequence represented by UniProtKB:P17050-1, in which the glycan structure is represented by GlyTouCan:G45359RY. Example: UniProtKB:P17050-1, Asn-177, MOD:00160~GNO:G45359RY.


Wormian bones

description: The presence of extra bones within a cranial suture. Wormian bones are irregular isolated bones which appear in addition to the usual centers of ossification of the cranium.


name: Elevated circulating 4-methyl-2-oxopentanoic acid concentration

description: The concentration of 4-methyl-2-oxopentanoic acid in the blood circulation is above the upper limit of normal.


name: BCAS3 microtubule associated cell migration factor isoform h4 (human)

description: A BCAS3 microtubule associated cell migration factor (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H6U6-8.


name: BCAS3 microtubule associated cell migration factor isoform h1 (human)

description: A BCAS3 microtubule associated cell migration factor (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H6U6-2.


name: BCAS3 microtubule associated cell migration factor phosphorylated 1 (human)

description: A BCAS3 microtubule associated cell migration factor (human) that has been phosphorylated on the residue at the position equivalent to Ser-180 of the amino acid sequence represented by UniProtKB:Q9H6U6-1. Example: UniProtKB:Q9H6U6-1, Ser-180, MOD:00046.


name: BCAS3 microtubule associated cell migration factor isoform 2 (human)

description: A BCAS3 microtubule associated cell migration factor isoform 1 that is encoded in the genome of human.


name: BCAS3 microtubule associated cell migration factor isoform h5 (human)

description: A BCAS3 microtubule associated cell migration factor (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H6U6-7.


name: BCAS3 microtubule associated cell migration factor isoform h3 (human)

description: A BCAS3 microtubule associated cell migration factor (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H6U6-3.


name: BCAS3 microtubule associated cell migration factor isoform h6 (human)

description: A BCAS3 microtubule associated cell migration factor (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H6U6-6.


pilaralisib

A sulfonamide that is the N-4-toluenesulfonyl (N-tosyl) derivative of N-(2,1,3-benzothiadiazol-5-yl)quinoxaline-2,3-diamine. A selective PI3K inhibitor used in cancer treatment.


A member of the class of thiophenes that is thiophene substituted by a carbonyl-L-arginine and (2,1,3-benzothiadiazole-4-sulfonyl)amino groups at positions 2 and 3. It is an inhibitor of the neuropilin-1 and VEGF-A interaction and a potential anti-cancer agent.


name: Abnormality of tumor necrosis factor secretion

description: An abnormality in the production or cellular release of tumor necrosis factor.


name: biogenesis of lysosome-related organelles complex 1 subunit 2 deaminated 1 (human)

description: A biogenesis of lysosome-related organelles complex 1 subunit 2 (human) that has been deaminated on the residue at the position equivalent to Gln-120 of the amino acid sequence represented by UniProtKB:Q6QNY1-1. Example: UniProtKB:Q6QNY1-1, Gln-120, MOD:00685.


atrioventricular septal defect 4

description: Any atrioventricular septal defect in which the cause of the disease is a mutation in the GATA4 gene.


name: structural congenital heart disease, multiple types - GATA4

description: Any congenital heart disease in which the cause of the disease is a mutation in the GATA4 gene.


ventricular septal defect 1

description: Any ventricular septal defect in which the cause of the disease is a mutation in the GATA4 gene.


name: heat shock factor 2-binding protein isoform h2 (human)

description: A heat shock factor 2-binding protein (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O75031-2.


name: heat shock factor 2-binding protein isoform h1 (human)

description: A heat shock factor 2-binding protein (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O75031-1.


name: T-cell surface glycoprotein CD4 N-glycosylated 23 (human)

description: A T-cell surface glycoprotein CD4 (human) that has been N-glycosylated at the residue equivalent to Asn-296 of the amino acid sequence represented by UniProtKB:P01730-1, in which the glycan structure is represented by GlyTouCan:G65890UA. Example: UniProtKB:P01730-1, Asn-296, MOD:00160~GNO:G65890UA.


name: Ras-related GTP-binding protein A deaminated 1 (human)

description: A Ras-related GTP-binding protein A (human) that has been deaminated on the residue at the position equivalent to Asn-30 of the amino acid sequence represented by UniProtKB:Q7L523. UniProtKB:Q7L523, Asn-30, MOD:00684.


name: peptide chain release factor 1-like, mitochondrial isoform h3 (human)

description: A peptide chain release factor 1-like, mitochondrial (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UGC7-3.


YINYANGHUO A

An extended flavonoid that is 2',2'-dimethyl-2'H,4H-2,6'-bichromen-4-one substituted by hydroxy groups at positions 5 and 7 and a 2-hydroxy-3-methylbut-3-en-1-yl group at position 8'. Isolated from Epimedium sagittatum, it exhibits inhibitory activity against platelet aggregation.


name: ATP-binding cassette sub-family A member 9 isoform h3 (human)

description: An ATP-binding cassette sub-family A member 9 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8IUA7-3.


Localized Parathyroid Gland Carcinoma

description: A parathyroid gland carcinoma that has not spread to other anatomic sites.


name: Nasopharyngeal Carcinoma by AJCC v7 Stage

description: A term that refers to the staging of nasopharyngeal carcinoma according to the American Joint Committee on Cancer, 7th edition.


name: Refractory Thyroid Gland Oncocytic Carcinoma

description: Thyroid gland oncocytic carcinoma that is resistant to treatment.


name: Stage II Differentiated Thyroid Gland Carcinoma AJCC v7

description: Stage II includes: Under 45 years: Any T, Any N, M1.  45 years and older: T2, N0, M0.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M1: Distant metastasis.  M0: No evidence of distant metastasis.  (from AJCC 7th Ed.)


name: Oropharyngeal (p16-Negative) Carcinoma by AJCC v8 Stage

description: A term that refers to the staging of p16-negative oropharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.


name: Thyroid Gland Sclerosing Mucoepidermoid Carcinoma with Eosinophilia

description: A rare type of mucoepidermoid carcinoma of the thyroid gland, usually associated with chronic lymphocytic thyroiditis.  It exhibits a unique morphologic appearance consisting of a squamoid, nested growth pattern, dense fibrosis, and mucinous differentiation.  The histogenesis of this unusual carcinoma has been debated, and it is unclear if it arises from remnants of the ultimobranchial body or from the follicular epithelial cells.


name: Stage I Thyroid Gland Follicular Carcinoma AJCC v8

description: Stage I includes: Under 55 years: Any T, Any N, M0. 55 years and older: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)


name: Unresectable Laryngeal Squamous Cell Carcinoma

description: Laryngeal squamous cell carcinoma that is not amenable to surgical resection.


name: Metastatic Nasopharyngeal Nonkeratinizing Carcinoma

description: Nasopharyngeal non-keratinizing carcinoma that has spread from its original site of growth to another anatomic site.


Stage IVC Laryngeal Cancer AJCC v8

description: Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


name: Hypopharyngeal Spindle Cell Squamous Carcinoma

description: A squamous cell carcinoma that arises from the hypopharynx. It is characterized by the presence of a malignant spindle cell cellular component. In some cases, there is a biphasic morphology due to the presence of a well-differentiated squamous cell carcinoma component. The latter is either in situ or invasive squamous cell carcinoma.


name: Metastatic Thyroid Gland Anaplastic Carcinoma

description: Thyroid gland anaplastic carcinoma that has spread from the original site of growth to another anatomic site.


name: Hypopharyngeal squamous cell carcinoma stage III

description: Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T3: Tumor measuring more than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus.  T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest dimension.  T2: Tumor invades more than one subsite of the hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest diameter without fixation of hemilarynx.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


name: Oropharyngeal Human Papillomavirus-Related Non-Keratinizing Squamous Cell Carcinoma

description: An oropharyngeal human papillomavirus-related squamous cell carcinoma characterized by the absence of keratinization and intercellular bridges.


name: Stage I Hypopharyngeal Carcinoma AJCC v6

description: Stage I includes: T1, N0, M0.  T1: Tumor limited to one subsite of the hypopharynx and 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th ed.)


name: Spindle Cell Variant Thyroid Gland Papillary Carcinoma

description: Papillary carcinoma of the thyroid gland with focal areas of spindle cell metaplasia.


Locally Advanced Laryngeal Carcinoma

description: Laryngeal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Carcinoma of pyriform fossa

description: A carcinoma that arises from the pyriform sinus.  Patients usually present with advanced stage disease and the prognosis is poor.


name: Refractory Differentiated Thyroid Gland Carcinoma

description: Differentiated thyroid gland carcinoma that is resistant to treatment.


Stage I Laryngeal Cancer AJCC v6 and v7

description: Stage I includes: T1, N0, M0.  T1: (Supraglottis) Tumor limited to one subsite of supraglottis with normal vocal cord mobility. (Glottis) Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility.  (Subglottis) Tumor limited to the subglottis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Laryngeal Cancer by AJCC v8 Stage

description: A term that refers to the staging of laryngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.


name: Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

description: Stage I includes: (T0, N0, M0); (T0, N1, M0); (T1, N0, M0); (T1, N1, M0); (T2, N0, M0); (T2, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in four or fewer lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8

description: Stage IVB includes: T4b, Any N, M0. T4b: Very advanced disease; tumor of any size with extension towards the spine or into nearby large blood vessels, invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels. M0: No distant metastasis. (from AJCC 8th Ed.)


name: Stage IVC Laryngeal Verrucous Carcinoma AJCC v7

description: Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 7th ed.)


name: Thyroid Gland Papillary Carcinoma with Fibromatosis/Fasciitis-Like/Desmoid-Type Stroma

description: A rare morphologic variant of papillary thyroid gland carcinoma characterized by the presence of abundant and cellular stroma resembling nodular fasciitis, fibromatosis, or other proliferative myofibroblastic processes. (WHO)


name: Stage I Thyroid Gland Follicular Carcinoma Under 55 Years AJCC v8

description: Stage I includes: Any T, Any N, M0. M0: No distant metastasis. (from AJCC 8th Ed.)


Stage II Laryngeal Cancer AJCC v8

description: Stage II includes: T2, N0, M0. T2: Supraglottis: Tumor invades the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Laryngeal verrucous carcinoma stage IV

description: Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1).  T4a: Supraglottis: Moderately advanced local disease.  Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus).  Glottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus).  Subglottis: Moderately advanced local disease.  Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus).  T4b: Supraglottis, Glottis, and Subglottis: Very advanced local disease.  Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)


name: Stage III Nasopharyngeal Carcinoma AJCC v7

description: Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  T3: Nasopharyngeal cancer with tumor involving bony structures of skull base and/or paranasal sinuses.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)


name: Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8

description: Stage IVA includes: 55 years and older: T4b, Any N, M0. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)


name: Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8

description: Stage IVC includes: Any T, Any N, M1. M1: distant metastasis. (AJCC 8th ed.)


name: Metastatic Thyroid Gland Follicular Carcinoma

description: A follicular carcinoma that arises from the thyroid gland and has metastasized to another anatomic site.


name: Stage IVA Nasopharyngeal Carcinoma AJCC v8

description: Stage IVA includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); (Any T, N3, M0); T4: Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle.  N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N2: Tumor with bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N3: Tumor with unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IVA Thyroid Gland Papillary Carcinoma AJCC v8


name: Hypopharyngeal Basaloid Squamous Cell Carcinoma

description: A high-grade, aggressive variant of squamous cell carcinoma that arises from the hypopharynx. It is characterized by the presence of small malignant cells with hyperchromatic nuclei and scant amount of cytoplasm forming lobules with peripheral palisading.


name: Stage IV Hypopharyngeal Carcinoma AJCC v6

description: Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (T4b, Any N, M0); (Any T, N3, M0); IVC (Any T, Any N, M1).  T4a: Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, esophagus, or central compartment soft tissue.  T4b: Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.  N2: Metastasis in a single ipsilateral lymph node, more than 3cm but not more than 6cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N2a: Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in greatest dimension.  N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension. N2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N3: Metastasis in a lymph node more than 6 cm in greatest dimension.  M1: Distant metastasis. (AJCC 6th ed.)


name: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

description: Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


name: Unresectable Nasopharyngeal Squamous Cell Carcinoma

description: Nasopharyngeal squamous cell carcinoma that is not amenable to surgical resection.


name: Stage IV Oropharyngeal Undifferentiated Carcinoma AJCC v7

description: Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (T4b, Any N, M0); (Any T, N3, M0); IVC (Any T, Any N, M1). T4a: Tumor with moderately advanced local disease.  Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible.  Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of larynx. T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  T3: Tumor measuring more than 4 centimeters in greatest dimension or extension to lingual surface of epiglottis.  T4b: Tumor with very advanced local disease.  Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Tumor with metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


Metastatic Hypopharyngeal Carcinoma

description: A carcinoma that arises from the hypopharynx and has metastasized to another anatomic site.


name: Stage II Thyroid Gland Follicular Carcinoma AJCC v8

description: Stage II includes: Under 55 years: Any T, Any N, M1; 55 years and older: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)


name: Stage IVB Oropharyngeal Undifferentiated Carcinoma AJCC v7

description: Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0). T4b: Tumor with very advanced local disease.  Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N3: Tumor with metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


name: Nasopharyngeal Small Cell Neuroendocrine Carcinoma

description: An extremely rare small cell neuroendocrine carcinoma that arises from the nasopharynx.


pharynx carcinoma in situ

description: Stage 0 carcinoma of the pharynx according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.


name: Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7

description: Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


name: Unresectable Oropharyngeal Squamous Cell Carcinoma

description: Oropharyngeal squamous cell carcinoma that is not amenable to surgical resection.


name: Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7

description: Stage IVB includes: T4b, Any N, M0. T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  M0: No distant metastasis. (AJCC 7th ed.)


Recurrent Thyroid Carcinoma

description: The reemergence of thyroid gland carcinoma after a period of remission.


carcinoma in situ of nasopharynx

description: A in situ carcinoma that involves the nasopharynx.


name: Nasopharyngeal lymphoepithelioma stage II

description: Stage II includes: (T1, N1, M0); (T2, N0, M0); (T2, N1, M0).  T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  M0: No distant metastasis. (AJCC 7th ed.)


name: papillary squamous cell carcinoma of larynx

description: A variant of squamous cell carcinoma that arises from the larynx. It is characterized by exophytic and papillary growth usually in the supraglottic area. The papillae are covered by a malignant stratified squamous epithelium.


name: Locally Recurrent Laryngeal Squamous Cell Carcinoma

description: The reemergence of laryngeal squamous cell carcinoma after a period of remission, at or adjacent to the site of the original tumor.


name: Oropharyngeal squamous cell carcinoma recurrent

description: Reemergence of squamous cell carcinoma of the oropharynx after a period of remission.


name: Hypopharyngeal squamous cell carcinoma recurrent

description: Reemergence of squamous cell carcinoma of the hypopharynx after a period of remission.


name: Metastatic Thyroid Gland Oncocytic Carcinoma

description: Thyroid gland oncocytic carcinoma that has spread from its original site of growth to another anatomic site.


carcinoma in situ of epiglottis

description: A in situ carcinoma that involves the epiglottis.


Pharyngeal Carcinoma by AJCC v7 Stage

description: A term that refers to the staging of pharyngeal carcinoma according to the American Joint Committee on Cancer, 7th edition.


name: Thyroid Gland Medullary Carcinoma by AJCC v7 Stage

description: A term that refers to the staging of thyroid gland medullary carcinoma, following the rules of the TNM AJCC v7 classification system.


name: mixed medullary-follicular thyroid carcinoma

description: A primary carcinoma of the thyroid gland containing a medullary carcinoma component that is immunohistochemically positive for calcitonin, and follicular carcinoma component that is immunohistochemically positive for thyroglobulin.


name: Stage III Thyroid Gland Follicular Carcinoma AJCC v8

description: Stage III includes: 55 years and older: T4a, Any N, M0. T4a: Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)


name: Advanced Laryngeal Squamous Cell Carcinoma

description: A squamous cell carcinoma of the larynx that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Stage II Thyroid Gland Papillary Carcinoma AJCC v7

description: Stage II includes: Under 45 years: Any T, Any N, M1.  45 years and older: T2, N0, M0.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M1: Distant metastasis.  M0: No evidence of distant metastasis.  (from AJCC 7th Ed.)


Laryngeal verrucous carcinoma recurrent

description: The reemergence of verrucous carcinoma of the larynx after a period of remission.


name: Oropharyngeal Poorly Differentiated Carcinoma

description: A high-grade carcinoma that arises from the oropharynx. It is characterized by the presence of malignant cells which bear minimal resemblance to the cells from which they arose.


name: Stage III Thyroid Gland Follicular Carcinoma AJCC v7

description: Stage III includes: (T3, N0, M0); (T1, N1a, M0); (T2, N1a, M0); (T3, N1a, M0). T3: Tumor greater than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  M0: No distant metastasis. (AJCC 7th ed.)


name: Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7

description: Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


name: Locally Recurrent Oropharyngeal Squamous Cell Carcinoma

description: The reemergence of oropharyngeal squamous cell carcinoma after a period of remission, at or adjacent to the site of the original tumor.


Stage IVC Pharyngeal Carcinoma

description: Stage IVC carcinoma of the pharynx according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.


name: Stage 0 Nasopharyngeal Undifferentiated Carcinoma AJCC v6, v7, and v8

description: Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th, 7th, and 8th eds.)


name: Stage IVB Oropharyngeal Carcinoma AJCC v7

description: Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0). T4b: Tumor with very advanced local disease.  Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N3: Tumor with metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


name: Stage III Differentiated Thyroid Gland Carcinoma AJCC v7


Oropharyngeal Neuroendocrine Carcinoma

description: An extremely rare neuroendocrine carcinoma that arises from the oropharynx.


Epiglottic Squamous Cell Carcinoma

description: A squamous cell carcinoma of the larynx that arises from the epiglottis.


name: Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v8

description: Stage IVB includes: (T1-T3a, N1, M0); (T3b, Any N, M0); (T4, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. T4: Tumor of any size with gross extrathyroidal extension. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)


name: Stage II Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8

description: Stage II includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)


name: Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7


name: Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7

description: Stage IV includes: IVA: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IVB (Any T, N3, M0); IVC (Any T, Any N, M1). T4: Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. N3: Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b.  M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)


name: Oropharyngeal Large Cell Neuroendocrine Carcinoma

description: An extremely rare large cell neuroendocrine carcinoma that arises from the oropharynx.


Refractory Nasopharyngeal Carcinoma

description: Nasopharyngeal carcinoma that is resistant to treatment.


name: Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

description: Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


name: Stage III Hypopharyngeal Carcinoma AJCC v7

description: Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T3: Tumor measuring more than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus.  T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest dimension.  T2: Tumor invades more than one subsite of the hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest diameter without fixation of hemilarynx.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


name: Locally Advanced Thyroid Gland Oncocytic Carcinoma

description: Thyroid gland oncocytic carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7

description: Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0).  T4b: Supraglottis: Very advanced local disease.  Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Glottis: Very advanced local disease.  Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Subglottis: Very advanced local disease.  Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures.  N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


name: Advanced Oropharyngeal Squamous Cell Carcinoma

description: A squamous cell carcinoma of the oropharynx that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

description: Stage I includes: (T0, N0, M0); (T0, N1, M0); (T1, N0, M0); (T1, N1, M0); (T2, N0, M0); (T2, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. M0: No distant metastasis. (AJCC 8th ed.)


name: Unresectable Thyroid Gland Oncocytic Carcinoma

description: Thyroid gland oncocytic carcinoma that is not amenable to surgical resection.


name: Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8

description: Stage II includes: T2, N0, M0. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Squamous cell carcinoma of the hypopharynx stage IV

description: A squamous cell carcinoma of the hypopharynx that has spread from the original site of growth to another anatomic site.


name: Stage II Thyroid Gland Follicular Carcinoma 55 Years and Older AJCC v8

description: Stage II includes: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)


name: Oncocytic Variant Thyroid Gland Papillary Carcinoma

description: A morphologic variant of papillary carcinoma of the thyroid gland characterized by the presence of papillary or follicular structures, containing malignant follicular cells with abundant granular eosinophilic cytoplasm. These cells have the nuclear features that characterize the papillary carcinomas of the thyroid gland.


name: Recurrent Hereditary Thyroid Gland Medullary Carcinoma

description: The reemergence of hereditary thyroid gland medullary carcinoma after a period of remission.


thyroid gland squamous cell carcinoma

description: A rapidly growing primary carcinoma of the thyroid gland composed of malignant squamous cells. The clinical course is usually aggressive.


name: Advanced Pharyngeal Squamous Cell Carcinoma

description: Pharyngeal squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7

description: Stage IVB includes: Any T, N3, M0.  N3: Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b.  M0: No distant metastasis. (AJCC 7th ed.)


name: Childhood Thyroid Gland Follicular Carcinoma

description: A follicular thyroid gland carcinoma occurring in childhood.


name: Oropharyngeal squamous cell carcinoma stage I

description: Stage I includes: T1, N0, M0.  T1: Tumor 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


name: Stage I Nasopharyngeal Carcinoma AJCC v8

description: Stage I includes: T1, N0, M0. T1: Tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IV Nasopharyngeal Carcinoma AJCC v6

description: Stage IV includes: IVA: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IVB (Any T, N3, M0); IVC (Any T, Any N, M1). T4: Tumor with intracranial extension and/or involvement of cranial nerves, infratemporal fossa, hypopharynx, orbit, or masticator space.  N3: Metastasis in a lymph node(s).  N3a: greater than 6 cm in dimension.  N3b: extension to the supraclavicular fossa.  M1: Distant metastasis. (AJCC 6th ed.)


name: Thyroid Gland Anaplastic Carcinoma by AJCC v8 Stage

description: A term that refers to the staging of thyroid gland anaplastic carcinoma, following the rules of the TNM AJCC v8 classification system.


Tonsillar Undifferentiated Carcinoma

description: A non-keratinizing carcinoma arising from the tonsil.  It is characterized by the presence of large malignant cells with vesicular nuclei, prominent nucleoli, syncytial growth pattern, and a lymphoplasmacytic infiltrate.


name: Thyroid Gland Follicular Carcinoma by AJCC v7 Stage

description: A term that refers to the staging of follicular thyroid gland carcinoma, following the rules of the TNM AJCC v7 classification system.


name: Stage III Laryngeal Cancer AJCC v6 and v7

description: Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Supraglottis: Tumor limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility.  Subglottis: Tumor limited to the subglottis.  T2: Supraglottis: Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx.  Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility.  Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. T3: Supraglottis: Tumor limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, pre-epiglottic tissues, paraglottic space, and/or inner cortex of thyroid cartilage.  Glottis: Tumor limited to the larynx with vocal cord fixation and/or invasion of paraglottic space, and/or inner cortex of the thyroid cartilage.  Subglottis: Tumor limited to larynx with vocal cord fixation.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3cm or less in greatest dimension.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Alcohol-Related Laryngeal Carcinoma

description: A carcinoma that arises from the larynx and is caused by alcohol abuse.


name: Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7

description: Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


name: Stage II Differentiated Thyroid Gland Carcinoma AJCC v8

description: Stage II includes: Under 55 years: Any T, Any N, M1; 55 years and older: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)


name: Stage 0 Laryngeal Verrucous Carcinoma AJCC v6, v7, and v8

description: Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th, 7th, and 8th eds.)


Pharyngeal cancer stage I

description: Stage I carcinoma of the pharynx according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.


name: Stage I Thyroid Gland Papillary Carcinoma 55 Years and Older AJCC v8

description: Stage I includes: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)


Stage IV Nasopharyngeal Carcinoma

description: A carcinoma that arises from the nasopharynx and has metastasized to another anatomic site.


name: Advanced Nasopharyngeal Squamous Cell Carcinoma

description: A squamous cell carcinoma of the nasopharynx that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Metastatic Tonsillar Squamous Cell Carcinoma

description: Tonsillar squamous cell carcinoma that has spread from its original site of growth to another anatomic site.


name: HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 Stage

description: A term that refers to the staging of HPV-mediated (p16-positive) oropharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.


name: Locally Advanced Parathyroid Gland Carcinoma

description: A parathyroid gland carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Unresectable Nasopharyngeal Carcinoma

description: Nasopharyngeal carcinoma that is not amenable to surgical resection.


name: Unresectable Hypopharyngeal Squamous Cell Carcinoma

description: Hypopharyngeal squamous cell carcinoma that is not amenable to surgical resection.


name: Stage III Hypopharyngeal Carcinoma AJCC v8

description: Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus. T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. T2: Tumor invading more than one subsite of hypopharynx or an adjacent site, or measuring more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). M0: No distant metastasis. (AJCC 8th ed.)


name: Unresectable Thyroid Gland Anaplastic Carcinoma

description: Thyroid gland anaplastic carcinoma that is not amenable to surgical resection.


name: Stage II Nasopharyngeal Carcinoma AJCC v8

description: Stage II includes: (T1, N1, M0); (T0, N1, M0); (T2, N0, M0); (T2, N1, M0). T1: Tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. T0: No tumor identified, but EBV-positive cervical node(s) involvement is present. T2: Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7


name: Hypopharyngeal Carcinoma by AJCC v8 Stage

description: A term that refers to the staging of hypopharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.


name: Nasopharyngeal Keratinizing Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the nasopharynx and is characterized by prominent production of keratin.


Laryngeal Basaloid Carcinoma

description: An aggressive variant of squamous cell carcinoma that arises from the pyriform sinus or supraglottic area.  It is characterized by the presence of small malignant cells with hyperchromatic nuclei and scant amount of cytoplasm forming lobules with peripheral palisading.  Comedonecrosis may be present.  An in situ or invasive keratinizing squamous cell carcinoma component is always present.  Signs and symptoms include hoarseness, dysphagia, pain, and neck mass.


Pharyngeal Carcinoma by AJCC v6 Stage

description: A term that refers to the staging of pharyngeal carcinoma according to the American Joint Committee on Cancer, 6th edition.


Stage IVA Laryngeal Cancer AJCC v7

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); T4a: Supraglottis: Moderately advanced local disease.  Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Glottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus). Subglottis: Moderately advanced local disease.  Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus).  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


name: Stage II Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7

description: Stage II includes: Any T, Any N, M1.  M1: Distant metastasis.  (from AJCC 7th Ed.)


name: Stage II Laryngeal Cancer AJCC v6 and v7

description: Stage II includes: T2, N0, M0. T2: (Supraglottis) Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx.  (Glottis) Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility.  (Subglottis) Tumor extends to vocal cord(s) with normal or impaired mobility. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


name: Classic Thyroid Gland Papillary Carcinoma

description: A thyroid gland papillary carcinoma characterized by the presence of thin cores of fibrovascular tissue lined by one or occasionally several layers of malignant cells with distinct nuclear features that include nuclear pseudoinclusions, nuclear grooves, and ground glass nuclear inclusions.


supraglottis squamous cell carcinoma

description: A squamous cell carcinoma of the larynx that arises from the supraglottic area. Signs and symptoms include dysphagia, a sensation of foreign body in the throat, and hemoptysis. It spreads to the space anterior to the epiglottis, pyriform sinus, and base of the tongue.


Stage IV Oropharyngeal Carcinoma

description: Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a: Tumor invades the larynx, deep/extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible. T4b: Tumor invades lateral pterygoid muscle, pterygoid plates lateral nasopharynx, or skull base or encases carotid artery. M1: Distant Metastasis. (AJCC 6th ed.)


laryngeal adenoid cystic carcinoma

description: A rare adenoid cystic carcinoma of the larynx. It usually arises from the supraglottic or subglottic area. It is characterized by slow progression and late distant metastases.


Hypopharyngeal Verrucous Carcinoma

description: An exophytic, warty, well differentiated, slow growing and non-metastasizing squamous cell carcinoma arising from the hypopharynx.


name: Stage 0 Hypopharyngeal Squamous Cell Carcinoma AJCC v6, v7, and v8

description: Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th, 7th, and 8th eds.)


name: Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7

description: Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis.  (AJCC 7th ed.)


name: Laryngeal Acantholytic Squamous Cell Carcinoma

description: A rare variant of squamous cell carcinoma that arises from the larynx.  It is characterized by acantholysis of the tumor cells that results in the formation of pseudolumina that resemble glandular structures.


description: A nasopharyngeal carcinoma characterized by the lack of keratinization and the presence of a dense lymphoplasmacytic infiltrate.  It is subdivided into undifferentiated and differentiated types, based on the cytologic features of the malignant cells.  The undifferentiated type is characterized by the presence of cells with large vesicular nuclei with prominent nucleoli and a syncytial pattern of growth.  The differentiated type is characterized by the presence of smaller cells and cellular stratification reminiscent of transitional cell carcinoma.  While morphologically distinct, both types have similar clinical presentation and prognosis.


larynx carcinoma in situ

description: A in situ carcinoma that involves the larynx.


Nasopharyngeal Basaloid Carcinoma

description: An aggressive variant of squamous cell carcinoma that arises from the nasopharynx.  It is characterized by the presence of small malignant cells with hyperchromatic nuclei and scant amount of cytoplasm forming lobules with peripheral palisading.  Comedonecrosis may be present.


name: Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7

description: Stage IVA includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)


name: Sporadic Thyroid Gland Micromedullary Carcinoma

description: A sporadic thyroid gland medullary carcinoma measuring less than 10mm in diameter.


name: Stage IV Nasopharyngeal Carcinoma AJCC v7

description: Stage IV includes: IVA: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IVB (Any T, N3, M0); IVC (Any T, Any N, M1). T4: Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. N3: Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b.  M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)


name: Recurrent Differentiated Thyroid Gland Carcinoma

description: The reemergence of differentiated thyroid gland carcinoma after a period of remission.


name: Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7

description: Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1).  T4a: Tumor with moderately advanced local disease.  Tumor invades the thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue.  Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.  T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest dimension.  T2: Tumor invades more than one subsite of the hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest diameter without fixation of hemilarynx.  T3: Tumor measuring more than 4 cm in greatest dimension or tumor with fixation of hemilarynx or extension to esophagus.  T4b: Tumor with very advanced local disease.  Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node more than 6 cm in greatest dimension.  M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


name: Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8

description: Stage IVB includes: 55 years and older: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)


name: Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

description: Stage II includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. N0: No regional lymph node metastasis. N1: Tumor with metastasis in four or fewer lymph nodes.  N2: Tumor with metastasis in more than four lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage I Thyroid Gland Papillary Carcinoma AJCC v8

description: Stage I includes: Under 55 years: Any T, Any N, M0. 55 years and older: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)


name: Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8

description: Stage IVA includes: (T4a, Any N, M0); (T1-3, N1b, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but less than 4 cm in greatest dimension limited to the thyroid. T3: Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. T4a: Moderately advanced disease; tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve. N1b: Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes levels I, II, III, IV, or V or retropharyngeal lymph nodes. M0: No distant metastasis. (from AJCC 8th Ed.)


name: Stage IVC Hypopharyngeal Carcinoma AJCC v8

description: Stage IVC includes: Any T, Any N, M1. M1: distant metastasis. (AJCC 8th ed.)


Laryngeal Giant Cell Carcinoma

description: A rare undifferentiated carcinoma that arises from the larynx.  It is characterized by the presence of multiple bizarre multinucleated giant cells.  The prognosis is poor.


name: Stage 0 Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v6, v7, and v8

description: Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th, 7th, and 8th eds.)


name: HPV positive oropharyngeal squamous cell carcinoma

description: A squamous cell carcinoma that arises from the oropharynx and is associated with human papillomavirus type 16 infection.


name: Refractory Laryngeal Squamous Cell Carcinoma

description: Laryngeal squamous cell carcinoma that does not respond to treatment.


name: Stage I Thyroid Gland Follicular Carcinoma 55 Years and Older AJCC v8

description: Stage I includes: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)


Unresectable Thyroid Gland Carcinoma

description: A carcinoma that arises from the thyroid gland and is not amenable to surgical resection.


Nasopharyngeal cancer recurrent

description: The reemergence of nasopharyngeal carcinoma after a period of remission.


name: Stage IV Thyroid Gland Medullary Carcinoma AJCC v8

description: Stage IV includes: IVA: (T4a, Any N, M0); (T1-3, N1b, M0); IVB: (T4b, Any N, M0); IVC: (Any T, Any N, M1). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but less than 4 cm in greatest dimension limited to the thyroid. T3: Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. T4a: Moderately advanced disease; tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve. T4b: Very advanced disease; tumor of any size with extension towards the spine or into nearby large blood vessels, invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels. N1b: Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes levels I, II, III, IV, or V or retropharyngeal lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)


name: thyroid gland diffuse sclerosing papillary carcinoma

description: A morphologic variant of papillary carcinoma of the thyroid gland that more often affects young patients and commonly metastasizing to the lungs. It is characterized by a diffuse infiltration of the thyroid gland by malignant follicular cells, squamous metaplasia, stromal fibrosis, and lymphocytic infiltration.


name: Refractory Thyroid Gland Follicular Carcinoma

description: Thyroid gland follicular carcinoma that is resistant to treatment.


name: Oropharyngeal Human Papillomavirus-Negative Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the oropharynx and lacks association with human papillomavirus type 16 infection.


name: Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Tumor with moderately advanced local disease.  Tumor invades the thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue.  Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.  T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest dimension.  T2: Tumor invades more than one subsite of the hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest diameter without fixation of hemilarynx.  T3: Tumor measuring more than 4 cm in greatest dimension or tumor with fixation of hemilarynx or extension to esophagus.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis.  (AJCC 7th ed.)


name: Stage IVB Nasopharyngeal Carcinoma AJCC v8

description: Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


name: Oropharyngeal Keratinizing Squamous Cell Carcinoma

description: An oropharyngeal squamous cell carcinoma characterized by the presence of keratinization and intercellular bridges.


Posterior Pharyngeal Wall Carcinoma

description: A carcinoma that arises from the posterior wall of the pharynx.


name: Nasopharyngeal squamous cell carcinoma stage I

description: Stage I includes: T1, N0, M0. T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)